Posts tagged ‘bladder cancer’
Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder.
Among both men and women, the rates of new cancers have decreased in recent years. Death rates, meanwhile, have declined among women and have held stable among men.
Specialists at City of Hope are internationally recognized experts in the treatment of bladder cancer. As one of a few institutions to attain the elite designation of comprehensive cancer center by the National Cancer Institute, City of Hope is acknowledged as a leader in cancer research and treatment.
City of Hope also offers numerous bladder cancer clinical trials and is constantly working to develop and deliver the latest treatment strategies for any stage of bladder cancer.
In this podcast, Bertram Yuh, M.D., discusses bladder cancer, how a person can lower his or her risk and what types of developments have been made in bladder cancer treatment in the past few years.
For other interviews with City of Hope experts, go to our list of City of Hope podcasts.
Learn more about becoming a patient or getting a second opinion at City of Hope by visiting our website or by calling 800-826-HOPE (4673). You may also request a new patient appointment online. City of Hope staff will explain what’s required for a consult at City of Hope and help you determine, before you come in, whether or not your insurance will pay for the appointment.
“With bladder cancer, the majority of patients that I see can be cured,” said urologist Kevin Chan, M.D., head of reconstructive urology at City of Hope. “The challenge is to get patients the same quality of life that they had before surgery.”
To meet this challenge, Chan and the urologic team at City of Hope ensure that bladder cancer patients who need a cystectomy, or bladder removal, are fully aware of their options. According to Chan, the majority of urologic surgeons will recommend only an “incontinent diversion,” in which the urine drains into an external bag.
But at City of Hope, 60 percent of patients receive “continent diversions” — either a neobladder or Indiana pouch—in which a section of intestine is used to create an internal reservoir. The neobladder allows patients to urinate out of their urethra, whereas the Indiana pouch results in a stoma on the abdomen that patients catheterize to empty.
“We spend an hour with each patient, explaining all three reconstructive procedures,” said Chan. “We go through the pros and cons of each one in that patient’s particular situation. And as long as it’s reasonable and makes sense from a cancer perspective, we will do everything we can to give them the reconstruction they want.” » Continue Reading
The American Society of Clinical Oncology (ASCO) is a U.S.-based organization that ties together oncology health care professionals (doctors, nurses and pharmacists) from around the world. The organization’s annual meeting represents a key forum in which scientific breakthroughs in oncology are unveiled. Attendance is nothing short of spectacular – last year, the meeting drew 34,000 attendees with just over half coming from outside of the U.S.
This year’s meeting begins Thursday in Chicago. After a busy clinic today, I’m going to hop on a red-eye and make my way there. As a medical oncologist focused on prostate, kidney and bladder cancer, I’ll be focused on the following research in particular:
1. “Gene therapy” for bladder cancer: The BOREALIS-1 trial: For years we have longed for new therapies for advanced bladder cancer. It’s been three decades since cisplatin (a standard chemotherapy agent) was introduced for the disease, and since that time, we’ve had virtually no effective drugs developed. This appears to be changing dramatically.
My friend and colleague Przemyslaw Twardowski, M.D., was involved in an international study evaluating a novel drug called apatorsen. Apatorsen represents a sort of “gene therapy” – a short strand of DNA that enters the cancer cell and shuts down its defense mechanisms. At this meeting, we will see data suggesting that when added to chemotherapy, apatorsen led to an impressive improvement in survival.
That data is a real glimmer of hope for patients with advanced bladder cancer. » Continue Reading
The treatment of urologic cancers, including bladder cancer, is rapidly evolving. Here, urologic oncologic surgeon and kidney stone specialist Donald Hannoun, M.D., an assistant clinical professor in the Division of Urology and Urologic Oncology at City of Hope | Antelope Valley, explains the changes in his field, as well as his approach to medicine.
Did someone or something from your early experience in life motivate you to go into medicine?
I’ve always loved working with people. I couldn’t think of a more altruistic field than medicine. What motivated me to get into urology was my late grandfather’s struggle with bladder stones, which are hard masses of minerals in the bladder. He was completely miserable before his surgery, and was then transformed into a new man after having them removed. To see such immediate results made me seriously consider urology. Now, I treat all types of genitourinary cancers, including kidney, bladder, prostate and testicular cancer.
Surgery for bladder cancer isn’t what it used to be; it’s better – much better. Advances in robotic surgeries have greatly improved both the options and the quality of life for people diagnosed with bladder cancer.
These advances, which are constantly giving way to even newer ones, mean that the entire bladder doesn’t always have to be removed. When it does, not only can highly skilled surgeons sometimes create an artificial bladder, they can even create an internal reservoir (different from a bladder and known as an Indiana pouch) using the large intestine and part of the small intestine. Such alternatives are usually preferred over the need for an external bag to collect the urine.
Much work remains, however, in the understanding of bladder cancer. Sumanta Pal, M.D., co-director of the Kidney Cancer Program at City of Hope, is leading several innovative studies in bladder cancer, with two of them focusing on what’s known as a molecular selection process. » Continue Reading